Wojciech Filipiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wojciech Filipiak has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Clemens Ager
Institute for Breath Research, University of Innsbruck, 6020 Innsbruck, Austria
17 shared publications - Jakob Troppmair
Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria
9 shared publications - Jochen K. Schubert
University Medicine Rostock
8 shared publications Andreas Sponring
Breath Research Institute of the Leopold Franzens University of Innsbruck
7 shared publicationsAnna Filipiak
Breath Research Institute of the University of Innsbruck, Dornbirn, Austria
7 shared publicationsAnton Amann
Breath Research Institute of the Leopold Franzens University of Innsbruck
7 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Validated thin-film microextraction-GC-MS reveals volatile metabolite signatures of Acinetobacter baumannii - Candida albicans interactions relevant to polymicrobial infection research
Background: Microbial volatile organic compounds (VOCs) may provide information on pathogenspecific metabolism and interspecies interactions, but their reliable characterization as potential indicators for diagnosis of emerging infections requires a robust analytical workflow. This study developed an in-house hydrophilic-lipophilic balanced (HLB) thin-film microextraction gas chromatography-mass spectrometry (TFME-GC-MS) workflow for dynamic VOC profiling of Acinetobacter baumannii, Candida albicans, and their mixed culture, to evaluate its applicability to microbial metabolomics in pre-clinical biomarker discovery. Methods: The workflow was optimized and subjected to validation using a panel of 20 VOCs in tryptic soy broth. The method showed compound-dependent analytical performance suitable for comparative microbial volatilomics, with negligible carryover and sufficient sensitivity for profiling dynamic VOC changes. Results: Application to mono- and co-cultures revealed distinct temporal VOC patterns associated with bacterial, fungal, and interaction-dependent metabolism. The multivariate analysis indicated that among the 145 VOCs monitored, 57 showed significant changes in A. baumannii cultures and 60 in C. albicans cultures, while 33 compounds supported differentiation of the investigated culture types based on VIP scores. The co-cultivation produced a VOC profile that could not be accounted for by summing the volatilomes of the individual monocultures, indicating metabolic interactions among the microorganisms. Calibration-based analysis of selected target VOCs further supported the profiling results for representative compounds. Conclusions: The proposed TFME-GC-MS method is a useful pharmaceutical-analysis tool for preclinical prioritization of volatile biomarker candidates relevant to future studies of polymicrobial infections.
- 10 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessValidated thin-film microextraction-GC-MS reveals volatile metabolite signatures of Acinetobacter baumannii - Candida albicans interactions relevant to polymicrobial infection research
Background: Microbial volatile organic compounds (VOCs) may provide information on pathogenspecific metabolism and interspecies interactions, but their reliable characterization as potential indicators for diagnosis of emerging infections requires a robust analytical workflow. This study developed an in-house hydrophilic-lipophilic balanced (HLB) thin-film microextraction gas chromatography-mass spectrometry (TFME-GC-MS) workflow for dynamic VOC profiling of Acinetobacter baumannii, Candida albicans, and their mixed culture, to evaluate its applicability to microbial metabolomics in pre-clinical biomarker discovery. Methods: The workflow was optimized and subjected to validation using a panel of 20 VOCs in tryptic soy broth. The method showed compound-dependent analytical performance suitable for comparative microbial volatilomics, with negligible carryover and sufficient sensitivity for profiling dynamic VOC changes. Results: Application to mono- and co-cultures revealed distinct temporal VOC patterns associated with bacterial, fungal, and interaction-dependent metabolism. The multivariate analysis indicated that among the 145 VOCs monitored, 57 showed significant changes in A. baumannii cultures and 60 in C. albicans cultures, while 33 compounds supported differentiation of the investigated culture types based on VIP scores. The co-cultivation produced a VOC profile that could not be accounted for by summing the volatilomes of the individual monocultures, indicating metabolic interactions among the microorganisms. Calibration-based analysis of selected target VOCs further supported the profiling results for representative compounds. Conclusions: The proposed TFME-GC-MS method is a useful pharmaceutical-analysis tool for preclinical prioritization of volatile biomarker candidates relevant to future studies of polymicrobial infections.
- 26 September 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1378, 344708
Assessment of thermal and solvent stable SPME fibers for volatilome investigation through in vitro experiments with cancer cell lines
- 26 September 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1378, 344708
Assessment of thermal and solvent stable SPME fibers for volatilome investigation through in vitro experiments with cancer cell lines
- Open Access
- 23 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8191
Profiling of Volatile Metabolites of Escherichia coli Using Gas Chromatography–Mass Spectrometry
Current diagnostic methods for bacterial infections in critically ill patients, including ventilator-associated pneumonia (VAP), are time-consuming, while empirical antibiotic therapy contributes to rising resistance. Bacteria-derived volatile organic compounds (VOCs) are being explored as specific biomarkers for pathogen identification and treatment monitoring. This study expands knowledge of Escherichia coli metabolism by identifying VOCs produced by both multidrug-resistant and susceptible strains, characterizing their temporal profiles during growth, and assessing VOC profile changes after imipenem exposure. Reference strains and 21 clinical isolates (derived from BAL samples of VAP patients) were cultured under controlled conditions. Headspace VOCs were preconcentrated using multibed sorption tubes and analyzed by gas chromatography–mass spectrometry (GC-MS), with compound identities confirmed using external standards. Sampling at seven time points over 24 h cultures revealed three VOC emission patterns: continuous release, temporary maximum, and compound uptake. In total, 57 VOCs were identified from the susceptible strain and 41 from the resistant one, with dimethyl disulfide, 2-butenal, ethyl acetate, and furan elevated in the resistant strain. Imipenem addition altered VOC production in the susceptible strain, with levels of six compounds elevated and seven reduced, while resistant profiles remained stable. Clinical isolates produced 71 VOCs, showing greater metabolic diversity and highlighting the relevance of isolate-derived VOCs in future studies.
- 23 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8191
Open AccessProfiling of Volatile Metabolites of Escherichia coli Using Gas Chromatography–Mass Spectrometry
Current diagnostic methods for bacterial infections in critically ill patients, including ventilator-associated pneumonia (VAP), are time-consuming, while empirical antibiotic therapy contributes to rising resistance. Bacteria-derived volatile organic compounds (VOCs) are being explored as specific biomarkers for pathogen identification and treatment monitoring. This study expands knowledge of Escherichia coli metabolism by identifying VOCs produced by both multidrug-resistant and susceptible strains, characterizing their temporal profiles during growth, and assessing VOC profile changes after imipenem exposure. Reference strains and 21 clinical isolates (derived from BAL samples of VAP patients) were cultured under controlled conditions. Headspace VOCs were preconcentrated using multibed sorption tubes and analyzed by gas chromatography–mass spectrometry (GC-MS), with compound identities confirmed using external standards. Sampling at seven time points over 24 h cultures revealed three VOC emission patterns: continuous release, temporary maximum, and compound uptake. In total, 57 VOCs were identified from the susceptible strain and 41 from the resistant one, with dimethyl disulfide, 2-butenal, ethyl acetate, and furan elevated in the resistant strain. Imipenem addition altered VOC production in the susceptible strain, with levels of six compounds elevated and seven reduced, while resistant profiles remained stable. Clinical isolates produced 71 VOCs, showing greater metabolic diversity and highlighting the relevance of isolate-derived VOCs in future studies.
- Open Access
- 6 March 2025
- Published by Elsevier in Green Analytical Chemistry
- Vol. 13
Protocol for the untargeted analysis of volatile metabolites in the headspace of biological samples using Thin-Film Microextraction coupled to GC–MS
- 6 March 2025
- Published by Elsevier in Green Analytical Chemistry
- Vol. 13
Open AccessProtocol for the untargeted analysis of volatile metabolites in the headspace of biological samples using Thin-Film Microextraction coupled to GC–MS
- Open Access
- 21 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1480
Analysis of Bacterial Metabolites in Breath Gas of Critically Ill Patients for Diagnosis of Ventilator-Associated Pneumonia—A Proof of Concept Study
Bacterial infection of the lower respiratory tract frequently occurs in mechanically ventilated patients and may develop into life-threatening conditions. Yet, existing diagnostic methods have moderate sensitivity and specificity, which results in the overuse of broad-spectrum antibiotics administered prophylactically. This study aims to evaluate the suitability of volatile bacterial metabolites for the breath-based test, which is used for diagnosing Ventilator-Associated Pneumonia (VAP). The in vitro experiments with pathogenic bacteria most prevalent in VAP etiology (i.e., Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) were performed to identify bacteria-derived metabolites using a specially designed cultivation system enabling headspace sampling for GC-MS analysis. Thirty-nine compounds were found to be significantly metabolized by tested species and, therefore, selected for monitoring in the exhaled breath of critically ill, mechanically ventilated (MV) patients. The emission of volatiles from medical respiratory devices was investigated to estimate the risk of spoiling breath results with exogenous pollutants. Bacterial metabolites were then evaluated to differentiate VAP patients from non-infected MV controls using Receiver Operating Characteristic (ROC) analysis, with AUC, sensitivity, and specificity calculated. Nine bacterial metabolites that passed verification through a non-parametric ANOVA test for significance and LASSO penalization were identified as key discriminators between VAP and non-VAP patients. The diagnostic model achieved an AUC of 0.893, with sensitivity and specificity values of 87% and 82.4%, respectively, being competitive with traditional methods. Further validation could solidify its clinical utility in critical care settings.
- 21 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1480
Open AccessAnalysis of Bacterial Metabolites in Breath Gas of Critically Ill Patients for Diagnosis of Ventilator-Associated Pneumonia—A Proof of Concept Study
Bacterial infection of the lower respiratory tract frequently occurs in mechanically ventilated patients and may develop into life-threatening conditions. Yet, existing diagnostic methods have moderate sensitivity and specificity, which results in the overuse of broad-spectrum antibiotics administered prophylactically. This study aims to evaluate the suitability of volatile bacterial metabolites for the breath-based test, which is used for diagnosing Ventilator-Associated Pneumonia (VAP). The in vitro experiments with pathogenic bacteria most prevalent in VAP etiology (i.e., Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) were performed to identify bacteria-derived metabolites using a specially designed cultivation system enabling headspace sampling for GC-MS analysis. Thirty-nine compounds were found to be significantly metabolized by tested species and, therefore, selected for monitoring in the exhaled breath of critically ill, mechanically ventilated (MV) patients. The emission of volatiles from medical respiratory devices was investigated to estimate the risk of spoiling breath results with exogenous pollutants. Bacterial metabolites were then evaluated to differentiate VAP patients from non-infected MV controls using Receiver Operating Characteristic (ROC) analysis, with AUC, sensitivity, and specificity calculated. Nine bacterial metabolites that passed verification through a non-parametric ANOVA test for significance and LASSO penalization were identified as key discriminators between VAP and non-VAP patients. The diagnostic model achieved an AUC of 0.893, with sensitivity and specificity values of 87% and 82.4%, respectively, being competitive with traditional methods. Further validation could solidify its clinical utility in critical care settings.
- Open Access
- 22 October 2024
- Published by MDPI AG in Preprints.org
Analysis of Bacterial Metabolites in Breath Gas of Critically Ill for Diagnosis of Ventilator-Associated Pneumonia—A Proof of Concept Study
Bacterial infection of the lower respiratory tract frequently occurs in mechanically ventilated pa-tients and may develop into life-threatening conditions. Yet existing diagnostic methods have moderate sensitivity and specificity, which results in the overuse of broad-spectrum antibiotics administrated prophylactically. This study aims to evaluate the suitability of volatile bacterial me-tabolites for breath-based test diagnosing Ventilation-Associated Pneumonia (VAP). The in vitro experiments with pathogenic microorganisms most prevalent in VAP patients (i.e., Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa) were performed to identify bacteria-derived metabolites using specially designed cultivation system enabling headspace sam-pling for GC-MS analysis. Thirty-nine compounds were found to be significantly metabolized by tested species and, therefore, selected for monitoring in the exhaled breath of critically ill, me-chanically ventilated (MV) patients. The emission of volatiles from medical respiratory devices was investigated to estimate the risk of spoiling breath results with exogenous pollutants. Bacterial metabolites were then evaluated to differentiate VAP patients from non-infected MV controls using receiver operating characteristic (ROC) analysis, with AUC, sensitivity, and specificity calculated. Nine bacterial metabolites that passed verification through a non-parametric ANOVA test for significance and LASSO penalization were identified as key discriminators between VAP and non-VAP patients. The diagnostic model achieved an AUC of 0.893, with sensitivity and specificity values of 87% and 82.4%, respectively, being competitive with traditional methods. Further vali-dation could solidify its clinical utility in critical care settings.
- 22 October 2024
- Published by MDPI AG in Preprints.org
Open AccessAnalysis of Bacterial Metabolites in Breath Gas of Critically Ill for Diagnosis of Ventilator-Associated Pneumonia—A Proof of Concept Study
Bacterial infection of the lower respiratory tract frequently occurs in mechanically ventilated pa-tients and may develop into life-threatening conditions. Yet existing diagnostic methods have moderate sensitivity and specificity, which results in the overuse of broad-spectrum antibiotics administrated prophylactically. This study aims to evaluate the suitability of volatile bacterial me-tabolites for breath-based test diagnosing Ventilation-Associated Pneumonia (VAP). The in vitro experiments with pathogenic microorganisms most prevalent in VAP patients (i.e., Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa) were performed to identify bacteria-derived metabolites using specially designed cultivation system enabling headspace sam-pling for GC-MS analysis. Thirty-nine compounds were found to be significantly metabolized by tested species and, therefore, selected for monitoring in the exhaled breath of critically ill, me-chanically ventilated (MV) patients. The emission of volatiles from medical respiratory devices was investigated to estimate the risk of spoiling breath results with exogenous pollutants. Bacterial metabolites were then evaluated to differentiate VAP patients from non-infected MV controls using receiver operating characteristic (ROC) analysis, with AUC, sensitivity, and specificity calculated. Nine bacterial metabolites that passed verification through a non-parametric ANOVA test for significance and LASSO penalization were identified as key discriminators between VAP and non-VAP patients. The diagnostic model achieved an AUC of 0.893, with sensitivity and specificity values of 87% and 82.4%, respectively, being competitive with traditional methods. Further vali-dation could solidify its clinical utility in critical care settings.
- Open Access
- 2 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 788
Molecular Analysis of Volatile Metabolites Synthesized by Candida albicans and Staphylococcus aureus in In Vitro Cultures and Bronchoalveolar Lavage Specimens Reflecting Single- or Duo-Factor Pneumonia
Current microbiological methods for pneumonia diagnosis require invasive specimen collection and time-consuming analytical procedures. There is a need for less invasive and faster methods to detect lower respiratory tract infections. The analysis of volatile metabolites excreted by pathogenic microorganisms provides the basis for developing such a method. Given the synergistic role of Candida albicans in increasing the virulence of pathogenic bacteria causing pneumonia and the cross-kingdom metabolic interactions between microorganisms, we compare the emission of volatiles from Candida albicans yeasts and the bacteria Staphylococcus aureus using single and mixed co-cultures and apply that knowledge to human in vivo investigations. Gas chromatography–mass spectrometry (GC-MS) analysis resulted in the identification of sixty-eight volatiles that were found to have significantly different levels in cultures compared to reference medium samples. Certain volatiles were found in co-cultures that mainly originated from C. albicans metabolism (e.g., isobutyl acetate), whereas other volatiles primarily came from S. aureus (e.g., ethyl 2-methylbutyrate). Isopentyl valerate reflects synergic interactions of both microbes, as its level in co-cultures was found to be approximately three times higher than the sum of its amounts in monocultures. Hydrophilic–lipophilic-balanced (HLB) coated meshes for thin-film microextraction (TFME) were used to preconcentrate volatiles directly from bronchoalveolar lavage (BAL) specimens collected from patients suffering from ventilation-associated pneumonia (VAP), which was caused explicitly by C. albicans and S. aureus. GC-MS analyses confirmed the existence of in vitro-elucidated microbial VOCs in human specimens. Significant differences in BAL-extracted amounts respective to the pathogen-causing pneumonia were found. The model in vitro experiments provided evidence that cross-kingdom interactions between pathogenic microorganisms affect the synthesis of volatile compounds. The TFME meshes coated with HLB particles proved to be suitable for extracting VOCs from human material, enabling the translation of in vitro experiments on the microbial volatilome to the in vivo situation involving infected patients. This indicates the direction that should be taken for further clinical studies on VAP diagnosis based on volatile analysis.
- 2 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 788
Open AccessMolecular Analysis of Volatile Metabolites Synthesized by Candida albicans and Staphylococcus aureus in In Vitro Cultures and Bronchoalveolar Lavage Specimens Reflecting Single- or Duo-Factor Pneumonia
Current microbiological methods for pneumonia diagnosis require invasive specimen collection and time-consuming analytical procedures. There is a need for less invasive and faster methods to detect lower respiratory tract infections. The analysis of volatile metabolites excreted by pathogenic microorganisms provides the basis for developing such a method. Given the synergistic role of Candida albicans in increasing the virulence of pathogenic bacteria causing pneumonia and the cross-kingdom metabolic interactions between microorganisms, we compare the emission of volatiles from Candida albicans yeasts and the bacteria Staphylococcus aureus using single and mixed co-cultures and apply that knowledge to human in vivo investigations. Gas chromatography–mass spectrometry (GC-MS) analysis resulted in the identification of sixty-eight volatiles that were found to have significantly different levels in cultures compared to reference medium samples. Certain volatiles were found in co-cultures that mainly originated from C. albicans metabolism (e.g., isobutyl acetate), whereas other volatiles primarily came from S. aureus (e.g., ethyl 2-methylbutyrate). Isopentyl valerate reflects synergic interactions of both microbes, as its level in co-cultures was found to be approximately three times higher than the sum of its amounts in monocultures. Hydrophilic–lipophilic-balanced (HLB) coated meshes for thin-film microextraction (TFME) were used to preconcentrate volatiles directly from bronchoalveolar lavage (BAL) specimens collected from patients suffering from ventilation-associated pneumonia (VAP), which was caused explicitly by C. albicans and S. aureus. GC-MS analyses confirmed the existence of in vitro-elucidated microbial VOCs in human specimens. Significant differences in BAL-extracted amounts respective to the pathogen-causing pneumonia were found. The model in vitro experiments provided evidence that cross-kingdom interactions between pathogenic microorganisms affect the synthesis of volatile compounds. The TFME meshes coated with HLB particles proved to be suitable for extracting VOCs from human material, enabling the translation of in vitro experiments on the microbial volatilome to the in vivo situation involving infected patients. This indicates the direction that should be taken for further clinical studies on VAP diagnosis based on volatile analysis.
- Open Access
- 16 April 2024
- Published by MDPI AG in Preprints.org
Molecular Analysis of Metabolites Synthesized by Candida albicans and Staphylococcus aureus in In Vitro Cultures and Bronchoalveolar Lavage Specimens Reflecting Single or Duo-factor Pneumonia
Current microbiological methods for pneumonia diagnosis require invasive specimen collection and time-consuming analytical procedures. There is a need for less invasive and faster methods to detect lower respiratory tract infection. The analysis of volatile metabolites excreted by pathogenic microorganisms provides the basis for developing such a method. Given the synergistic role of Candida albicans in increasing the virulence of pathogenic bacteria causing pneumonia and the cross-kingdom metabolic interactions between microorganisms, we compare the emission of volatiles from Candida albicans yeasts and the bacteria Staphylococcus aureus using single and mixed co-cultures and apply that knowledge to human in vivo investigations. Gas-chromatography-mass spectrometry (GC-MS) analysis resulted in the identification of sixty-eight volatiles that were found to have significantly different levels in cultures compared to reference medium samples. Certain volatiles found in co-culture originated mainly from C. albicans metabolism (e.g., isobutyl acetate), whereas other volatiles primarily came from S. aureus (e.g., ethyl 2-methylbutyrate). Isopentyl valerate reflects synergic interactions of both microbes, as its level in co-cultures was found to be approximately three times higher than the sum of its amounts in monocultures. Hydrophilic-lipophilic balanced (HLB) coated meshes for thin-film microextraction (TFME) were used to pre-concentrate volatiles directly from bronchoalveolar lavage (BAL) specimens collected from patients suffering from ventilation-associated pneumonia (VAP) that was caused explicitly by C. albicans and S. aureus. GC-MS analyses confirmed the existence of in vitro-elucidated microbial VOCs in human specimens. Significant differences in BAL-extracted amounts respective to the pathogen causing pneumonia were found. The model in vitro experiments provided evidence that cross-kingdom interactions between pathogenic microorganisms affect the synthesis of the volatile compounds. The TFME meshes coated with HLB particles proved to be suitable for extracting VOCs from human material, enabling the translation of in vitro experiments on the microbial volatilome to the in vivo situation involving infected patients. This indicates the direction that should be taken for further clinical studies on VAP diagnosis based on volatile analysis.
- 16 April 2024
- Published by MDPI AG in Preprints.org
Open AccessMolecular Analysis of Metabolites Synthesized by Candida albicans and Staphylococcus aureus in In Vitro Cultures and Bronchoalveolar Lavage Specimens Reflecting Single or Duo-factor Pneumonia
Current microbiological methods for pneumonia diagnosis require invasive specimen collection and time-consuming analytical procedures. There is a need for less invasive and faster methods to detect lower respiratory tract infection. The analysis of volatile metabolites excreted by pathogenic microorganisms provides the basis for developing such a method. Given the synergistic role of Candida albicans in increasing the virulence of pathogenic bacteria causing pneumonia and the cross-kingdom metabolic interactions between microorganisms, we compare the emission of volatiles from Candida albicans yeasts and the bacteria Staphylococcus aureus using single and mixed co-cultures and apply that knowledge to human in vivo investigations. Gas-chromatography-mass spectrometry (GC-MS) analysis resulted in the identification of sixty-eight volatiles that were found to have significantly different levels in cultures compared to reference medium samples. Certain volatiles found in co-culture originated mainly from C. albicans metabolism (e.g., isobutyl acetate), whereas other volatiles primarily came from S. aureus (e.g., ethyl 2-methylbutyrate). Isopentyl valerate reflects synergic interactions of both microbes, as its level in co-cultures was found to be approximately three times higher than the sum of its amounts in monocultures. Hydrophilic-lipophilic balanced (HLB) coated meshes for thin-film microextraction (TFME) were used to pre-concentrate volatiles directly from bronchoalveolar lavage (BAL) specimens collected from patients suffering from ventilation-associated pneumonia (VAP) that was caused explicitly by C. albicans and S. aureus. GC-MS analyses confirmed the existence of in vitro-elucidated microbial VOCs in human specimens. Significant differences in BAL-extracted amounts respective to the pathogen causing pneumonia were found. The model in vitro experiments provided evidence that cross-kingdom interactions between pathogenic microorganisms affect the synthesis of the volatile compounds. The TFME meshes coated with HLB particles proved to be suitable for extracting VOCs from human material, enabling the translation of in vitro experiments on the microbial volatilome to the in vivo situation involving infected patients. This indicates the direction that should be taken for further clinical studies on VAP diagnosis based on volatile analysis.
- Open Access
- 28 November 2023
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 14 (4) , 100898
Modern approaches for detection of volatile organic compounds in metabolic studies focusing on pathogenic bacteria: Current state of the art
- 28 November 2023
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 14 (4) , 100898
Open AccessModern approaches for detection of volatile organic compounds in metabolic studies focusing on pathogenic bacteria: Current state of the art
- Open Access
- 18 October 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 1019290
GC-MS profiling of volatile metabolites produced by Klebsiella pneumoniae
Currently used methods for diagnosing ventilator-associated pneumonia (VAP) are complex, time-consuming and require invasive procedures while empirical antibacterial therapy applies broad spectrum antibiotics that may promote antimicrobial resistance. Hence, novel and fast methods based on alternative markers are needed for VAP detection and differentiation of causative pathogens. Pathogenic bacteria produce a broad range of volatile organic compounds (VOCs), some of which may potentially serve as biomarkers for microorganism identification. Additionally, monitoring of dynamically changing VOCs concentration profiles may indicate emerging pneumonia and allow timely implementation of appropriate antimicrobial treatment. This study substantially extends the knowledge on bacterial metabolites providing the unambiguous identification of volatile metabolites produced by carbapenem-resistant and susceptible strains of Klebsiella pneumoniae (confirmed with pure standards in addition to mass spectra match) but also revealing their temporary concentration profiles (along the course of pathogen proliferation) and dependence on the addition of antibiotic (imipenem) to bacteria. Furthermore, the clinical strains of K. pneumoniae isolated from bronchoalveolar lavage specimens collected from mechanically ventilated patients were investigated to reveal, whether bacterial metabolites observed in model experiments with reference strains could be relevant for wild pathogens as well. In all experiments, the headspace samples from bacteria cultures were collected on multibed sorption tubes and analyzed by GC-MS. Sampling was done under strictly controlled conditions at seven time points (up to 24 h after bacteria inoculation) to follow the dynamic changes in VOC concentrations, revealing three profiles: release proportional to bacteria load, temporary maximum and uptake. Altogether 32 VOCs were released by susceptible and 25 VOCs by resistant strain, amongst which 2-pentanone, 2-heptanone, and 2-nonanone were significantly higher for carbapenem-resistant KPN. Considerably more metabolites (n = 64) were produced by clinical isolates and in higher diversity compared to reference KPN strains.
- 18 October 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 1019290
Open AccessGC-MS profiling of volatile metabolites produced by Klebsiella pneumoniae
Currently used methods for diagnosing ventilator-associated pneumonia (VAP) are complex, time-consuming and require invasive procedures while empirical antibacterial therapy applies broad spectrum antibiotics that may promote antimicrobial resistance. Hence, novel and fast methods based on alternative markers are needed for VAP detection and differentiation of causative pathogens. Pathogenic bacteria produce a broad range of volatile organic compounds (VOCs), some of which may potentially serve as biomarkers for microorganism identification. Additionally, monitoring of dynamically changing VOCs concentration profiles may indicate emerging pneumonia and allow timely implementation of appropriate antimicrobial treatment. This study substantially extends the knowledge on bacterial metabolites providing the unambiguous identification of volatile metabolites produced by carbapenem-resistant and susceptible strains of Klebsiella pneumoniae (confirmed with pure standards in addition to mass spectra match) but also revealing their temporary concentration profiles (along the course of pathogen proliferation) and dependence on the addition of antibiotic (imipenem) to bacteria. Furthermore, the clinical strains of K. pneumoniae isolated from bronchoalveolar lavage specimens collected from mechanically ventilated patients were investigated to reveal, whether bacterial metabolites observed in model experiments with reference strains could be relevant for wild pathogens as well. In all experiments, the headspace samples from bacteria cultures were collected on multibed sorption tubes and analyzed by GC-MS. Sampling was done under strictly controlled conditions at seven time points (up to 24 h after bacteria inoculation) to follow the dynamic changes in VOC concentrations, revealing three profiles: release proportional to bacteria load, temporary maximum and uptake. Altogether 32 VOCs were released by susceptible and 25 VOCs by resistant strain, amongst which 2-pentanone, 2-heptanone, and 2-nonanone were significantly higher for carbapenem-resistant KPN. Considerably more metabolites (n = 64) were produced by clinical isolates and in higher diversity compared to reference KPN strains.